［1］ YOON,YOUNG SO,JEEYOUNG OH.Neuropathic cancer pain:prevalence,pathophysiology, and management［J］.The Korean Journal of Internal Medicine,2018,33(6):1058.
［2］ TREEDE RD,JENSEN TS,CAMPBELL JN.Neuropathic pain:redefinition and a grading system for clinical and research purposes［J］. Neurology,2008,70(18):1630-1635.
［3］ LEMA MJ,FOLEY KM,HAUSHEER FH.Types and epidemiology of cancer-related neuropathic pain:the intersection of cancer pain and neuropathic pain［J］.The Oncologist,2010,15(S2):3-8.
［4］ SHKODRA M,CARACENI A.Treatment of neuropathic pain directly due to cancer:an update［J］.Cancers (Basel),2022,14(8):1992.
［5］ 武思尹,马柯.癌痛治疗中阿片镇痛耐受的研究进展［J］.中国疼痛医学杂志,2022,28(05):375-378.
WU SY,MA K.Progress in opioid analgesic tolerance in the treatment of cancer pain［J］.Chinese Journal of Pain Medicine,2022,28(05):375-378.
［6］ FAN X,GONG M,ZHANG S.Blocking palmitoylation of apelin receptor alleviates morphine tolerance in neuropathic cancer pain［J］.International Journal of Biological Sciences,2024,20(1):47-60.
［7］ 王稳,樊碧发.癌痛发生机制的研究进展［J］.中国疼痛医学杂志,2021,27(08):616-618.
WANG W,FAN BF.Progress in the mechanism of cancer pathogenesis［J］.Chinese Journal of Pain Medicine,2021,27(08):616-618.
［8］ WANG Z,PATEL DJ.Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases［J］.Quarterly Reviews of Biophysics,2013,46(4):349-373.
［9］ CODERRE TJ,XANTHOS DN,FRANCIS L.Chronic post-ischemia pain (CPIP):a novel animal model of complex regional pain syndrome-type Ⅰ(CRPS-I,reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat［J］.Pain,2004,112(1-2):94-105.
［10］ SCHMIDT BL,PICKERING V,LIU S.Peripheral endothelin a receptor antagonism attenuates carcinoma-induced pain［J］.Eur J Pain,2007,11(4):406-414.
［11］ QUANG PN,SCHMIDT BL.Endothelin-a receptor antagonism attenuates carcinoma-induced pain through opioids in mice［J］.Pain,2010,11(7):663-671.
［12］ KAWAMATA T,JI W,YAMAMOTO J.Involvement of transient receptor potential vanilloid subfamily 1 in endothelin-1-induced pain-like behavior［J］.Neuroreport,2009,20(3):233-237.
［13］ WATSON JJ,ALLEN SJ,WINKLER JJ.Targeting nerve growth factor in pain:what is the therapeutic potential［J］.Bio Drugs,2008,22(6):349-359.
［14］ YE Y,DANG D,YU H.Nerve growth factor links oral cancer progression,pain,and cachexia［J］.Mol Cancer Ther,2011,10(9):1667-1676.
［15］ LIANG ZJ,TAN J,TANG L,et al.NGF monoclonal antibody DS002 alleviates chemotherapy-induced peripheral neuropathy in rats［J］.Acta Pharmacologica Sinica,2022,43(11):2841-2847.
［16］ CHANG DS, HSU E,HOTTINGER DG.Anti-nerve growth factor in pain management:current evidence［J］.Journal of Pain Research,2016,9:373-383.
［17］ BAE J,KIM YO,NOORI M.Synthesis and structure-activity relationship studies of benzimidazole-4,7-dione-based P2X3 receptor antagonists as novel anti-nociceptive agents［J］.Molecules,2022,27(4):1337.
［18］ DRILL M,JONES NC,HUNN M.Antagonism of the ATP-gated P2X7 receptor:a potential therapeutic strategy for cancer［J］.Purinergic Signal,2021,17(2):215-227.
［19］ YE Y,ONO K,BERNABE DG.Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers［J］.Acta Neuropathol Commun,2014,2:62.
［20］ DE ALMEIDA AS, BERNARDES LB,TREVISAN G.TRP channels in cancer pain［J］.European Journal of Pharmacology,2021,904:174185.
［21］ BUJAK JK,KOSMALA D,SZOPA IM.Inflammation,cancer and immunity-implication of TRPV1 channel［J］.Front Oncol,2019,9:1087.
［22］ AMADESI S,COTTRELL GS,DIVINO L.Protease-activated receptor 2 sensitizes TRPV1 by protein kinase cepsilon- and a-dependent mechanisms in rats and mice［J］. The Journal of Physiology,2006,575(2):555-571.
［23］ ANTONIAZZI CTD,NASSINI R,RIGO FK.Transient receptor potential ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer pain［J］.International Journal of Cancer,2019,144(2):355-365.
［24］ BRUSCO I,LI PUMA S,CHIEPE KB.Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice［J］.International Journal of Cancer,2020,146(10):2797-2809.
［25］ DE LOGU F,TREVISAN G,MARONE IM.Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4［J］.BMC Biology,2020,18(1):197.
［26］ TODA T,YAMAMOTO S,YONEZAWA R.Inhibitory effects of tyrphostin AG-related compounds on oxidative stress-sensitive transient receptor potential channel activation［J］.European Journal of Pharmacology,2016,786:19-28.
［27］ HUNG CH,CHIN Y,FONG YO.Acidosis-related pain and its receptors as targets for chronic pain［J］.Pharmacology & Therapeutics,2023,247:108444.
［28］ OMORI M,YOKOYAMA M,MATSUOKA Y.Effects of selective spinal nerve ligation on acetic acid-induced nociceptive responses and ASIC3 immunoreactivity in the rat dorsal root ganglion［J］.Brain Research,2008,1219:26-31.
［29］ SOMMER C,LEINDERS M,UCEYLER N.Inflammation in the pathophysiology of neuropathic pain［J］.Pain,2018,159(3):595-602.
［30］ MA H,PAN Z,LAI B.Contribution of immune cells to cancer-related neuropathic pain:An updated review［J］.Molecular Pain,2023,19:17448069231182235.
［31］ CALVO M,DAWES JM,BENNETT DL.The role of the immune system in the generation of neuropathic pain［J］.The Lancet Neurology,2012,11(7):629-642.
［32］ BETHEA JR,FISCHER R.Role of peripheral immune cells for development and recovery of chronic pain［J］.Frontiers in Immunology,2021,12:641588.
［33］ SHARIFI L,NOWROOZI MR,AMINI E.A review on the role of M2 macrophages in bladder cancer,pathophysiology and targeting［J］.International Immunopharmacology,2019,76:105880.
［34］ GOTO T,VON AH D,LI X.Brain-derived neurotrophic factor rs6265 polymorphism is associated with severe cancer-related fatigue and neuropathic pain in female cancer survivors［J］.Journal of Cancer Survivorship,2023,1-10:37462904.
［35］ LI QY,XU HY,YANG HJ.Effect of proinflammatory factors TNF-α,IL-1β,IL-6 on neuropathic pain［J］.China Journal of Chinese Materia Medica,2017,42(19):3709-3712.
［36］ LIU Q,CHEN W,FAN X.Upregulation of interleukin-6 on Cav3.2 T-type calcium channels in dorsal root ganglion neurons contributes to neuropathic pain in rats with spinal nerve ligation［J］.Experimental Neurology,2019,317:226-243.
［37］ FANG D,KONG LY,CAI J.Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway:roles in the development of bone cancer pain in a rat model［J］.Pain,2015,156(6):1124-1144.
［38］ LEO M,SCHULTE M,SCHMITT LI.Intrathecal resiniferatoxin modulates TRPV1 in DRG neurons and reduces TNF-induced pain-related behavior［J］.Mediators of Inflammation,2017,2017(1):2786427.
［39］ ZHOU YQ,LIU Z,LIU ZH.Interleukin-6:an emerging regulator of pathological pain［J］.Journal of Neuroinflammation,2016,13(1):141.
［40］ JI RR,SUTER MR.p38 MAPK,microglial signaling,and neuropathic pain［J］.Molecular Pain,2007,3:33.
［41］ LAUGHLIN TM,BETHEA JR,YEZIERSKI RP.Cytokine involvement in dynorphin-induced allodynia［J］.Pain,2000,84(2-3):159-167.
［42］ 张文颖,姜斌.癌痛发生机制的研究进展［J］.现代肿瘤医学,2019,27(10):1845-1848.
ZHANG WY,JIANG B.Progress in the mechanism of cancer pathogenesis［J］.Modern Oncology,2019,27(10):1845-1848.
［43］ GIRI SS,TRIPATHI AS,ERKEKOGLU P.Molecular pathway of pancreatic cancer-associated neuropathic pain［J］.Journal of Biochemical Toxicology, 2024,38(4):e23638.